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The Design of Potential Anti-Parkinsonian Drugs: What is the
Dopaminergic Pharmacophore in Ergot Alkaloids? 1
JOSEPH G. CANNON
Division of Medicinal and Natural Products Chemistry, College of Pharmacy,
The University of Iowa, Iowa City, Iowa 52242
The problem of defining structural similarities between apomorphine and certain ergot alkaloid derivatives, two chemically dissimilar
types of drugs having similar pharmacological effects, is addressed by considering the three-dimensional geometry of the molecules.
Conformational analytical concepts can be used to design new chemical entities and to assess structure-activity relationship hypotheses,
and indeed this strategy has led to synthesis of new categories of potentially clinically valuable agents.
Some conclusions are presented with respect to the combinations of atoms within the molecules in various chemical categories of
dopaminergic agonists, which are responsible for the observed pharmacological effects. On the basis of these conclusions, some general
properties of in vivo dopamine receptors are inferred, and proposals are advanced for structural analysis of the molecule of dopamine itself,
which may be applicable to the design of new, superior therapeutic agents for those pathological conditions which are referrable to the
dopaminergic nervous system.
INDEX DESCRIPTORS: dopaminergic pharmacophore; ergot alkaloids; structure-activity relationships; drug design

The biochemical involvement of the neurotransmitter substance
dopamine 1 in the Parkinsonian syndrome is well established, and the
most successful therapeutic strategy has been the administration of a
drug (either a biochemical precursor to dopamine itself, or a synthetic
dopaminergic agonist), for the purpose of stimulating the remaining,
intact hyperresponsive dopamine receptors in the nigrostriatal pathway in the brain, in order to relieve the abnormalities of muscular
control.
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Among the agents which have elicited some clinical interest is a
semi-synthetic derivative of the ergot alkaloid family, a derivative of
the ergoline ring system, bromocriptine 2. Indeed, dopaminergic
agonist effects have been noted in a variety of ergoline derivatives:
lergotrile 3, pergolide 4, and lisuride 5, in addition to bromocriptine.
It is established that the significant biological effects of these compounds reside in the ergoline ring system, and not in the variety of
complex substituents on the molecule. In addition to their effects on
dopaminergic mechanisms, many of the ergolines have a high affiniry
for a-adrenoceptors and for serotonin receptors.
Thus, the pharmacologic profile noted for these drugs is the sum total
of their effects on dopamine receptors, norepinephrine a-receptors,
and serotonin receptors. It seems probable that any drug derived from
the ergoline ring system will possess a broad spectrum of side effects.
Certainly, one of the most important features of any clinically useful
anti-Parkinsonian agent must be a high degree of pharmacologic
specificity and freedom from serious side effects. An added complication is the fact that lergotrile 3 is metabolized to a 13-hydroxy
metabolite 6 which is exponentially more potent than lergotrile itself
in several animal assays (2), and which is believed to be responsible for
the preponderance of the observed dopaminergic effects of the drug. It
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is appealing to propose that lergotrile is a prodrug to its 13-hydroxy
metabolite. However, not all of the ergot derivatives require this
metabolic activation; bromocriptine, for example, is active as such.
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The observed effects of these molecules at serotonin receptors can be
rationalized. It is apparent that the ergoline system 7 contains an
indole-3-ethylamine moiety analogous to serotonin 8; thus, the
ergolines may have an affinity for serotonin receptors because the
receptors recognize the ergoline ring as being structurally like serotonin.

ical dopaminergic agonist, which is frequently used as a reference
standard drug, for comparison with other dopamine-like synthetic
agents.
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It is apparent that the hydrogen in the ergoline system is pointed back
behind the plane of the page, and the equivalent hydrogen in
apomorphine is projected out in front of the plane of the page. Nichols
rationalized the pharmacological differences in these absolute configurations upon the premise that the rigidly held pyrrole-3-ethylamine
moiety of the ergoline ring system (outlined in heavy lines in structure
13) corresponds to the ~-3,4-dihydroxyphenethylamine moiety within the apomorphine molecule (outlined in heavy lines in structure 14),
and indeed that this pyrrole ethylamine moiety represents the dopaminergic pharmacophore in the ergolines. The emphasized portion of
the ergoline ring system 13 is biochemically equivalent to the
emphasized portion of the apomorphine system 14. Nichols drew the
two ring systems from a different perspective to emphasize these ideas.

10

R
However, rationalization of a close structural similarity between the
ergoline derivatives and dopamine is not quite as obvious or facile.
While there is a ~-phenethylamine moiety 10 in the ergoline system
analogous to that in dopamine (illustrated in structure 9), the ergoline
system in several very potent dopaminergic molecules lacks the
catechol di-OH moiety of dopamine (and, indeed, sometimes lacks
any phenolic groups whatsoever). It is well established that unsubstituted ~-phenethylamine 10 is devoid of effects at dopamine
receptors, and it is this combination of atoms that is contained in most
of the dopaminergic ergoline derivatives. Therefore, the medicinal
chemists posed the questions: "What is the dopaminergic pharmacophore in the ergoline ring system?" To what combination of
atoms is the affinity of these ergot derivatives for dopamine receptors
due?"
Nichols (3) attacked the problem by first noting that the dopaminergically active ergoline derivatives (typified by lergotrile, structure
11) appear to have the "wrong" absolute configuration at the chiral
center (position 5) which forms a part of the ~-phenethylamine
moiety, in comparison with the analogous carbon (6a) in the biologically active enantiomer, (R)-(-)-apomorphine (structure 12), a prototyp-
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In 15, the ergoline ring system has been turned on its opposite face,
and it and the apomorphine molecule 16 have been rotated in the
plane of the page. Priority was placed on correspondence at the chiral
carbons and the aliphatic ring nitrogen, as shown. The 2,3,4,5,6
positions of the ergoline system were proposed to correspond to and to
superimpose upon the 6, 6a, 7, 7a, 8 positions ofapomorphine. Thus,
the 2- position of the ergolines corresponds to the 8- position of
apomorphine and to the 8- position of the 2-aminotetralins 17. These
2-aminotetralins represent a fragment of the apomorphine molecule,
as well as being congeners of dopamine. They have the same
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stereochemical properties as apomorphine; they have the same molecular shape and, like apomorphine, they are very potent dopaminergic
agonists.
Nichols suggested that the C-10 hydroxy of apomorphine is in
about the same position in space relative to the basic nitrogen as is the
indole N-H of the ergolines, relative to its basic nitrogen. Analysis of
molecular models by us did not confirm this: the distance between
N-6 and the indole ring nitrogen (N-1) in the ergoline ring system
(structure 18) is approximately 6. 5 A, and the nitrogen-to-C-10 OH
distance in apomorphine (structure 19) is approximately 7. 8 A. It
seems to follow from the Nichols proposals that the pyrrole ring N-H
of the ergolines and the C-10 ("para") OH of apomorphine are
biologically equivalent for interaction with the same subsite on the
dopamine receptor(s).
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However, consideration of pharmacological data (4) on the monohydroxylated congeners of apomorphine (structure 20) indicates that
the 10-monohydroxy molecule is not a direct acting dopaminergic
agonist, and is not very active/potent. The 9-hydroxy isomer is inert.
Significant dopaminergic effect is present only in the 11-monohydroxy derivative, which does not appear to provide a close superimposition upon the proposed corresponding region in the ergoline
system. The Nichols structural correlations are intriguing with
respect to comparison of chiral centers, but it seems that the structural
ideas involving interatomic distances are less impressive, in that the
ergoline structures fit and compare best with structures of inactive
apomorphine derivatives.
A test of any structure-activity proposal is its utility in design of
new agents having the desired biological activity and high potency.
Kornfeld and co-workers at Eli Lilly and Company accepted the
hypothesis that in the ergoline class, the rigid pyrrole-3-ethylamine
moiety rather than the ~-phenethylamine moiety is responsible for
dopamine agonist properties. To test the hypothesis, they designed
and synthesized a series of ergoline partial structures (5 ).

pyrrole-3-ethylamine and the ~-phenethylamine moieties. Structures
22 and 23 showed dopamine-like effects, albeit of much lower
potency than (e.g.) pergolide. These were the first non-benzene
derived molecules for which significant dopaminergic effect has been
reported. These results were taken as strong support for the hypothesis
that the dopaminergic pharmacophore in the ergolines is the pyrrole3-ethylamine. These molecules bear n-propyl groups on the basic
nitrogen. It is an empirical observation, noted first by us and
subsequently verified many times, that n-propyl groups enhance
dopaminergic agonist effect, even to the extent of conferring agonist
effects upon some molecules that were inert or nearly so when they
bore hydrogen or methyl on the basic nitrogen.
A detriment to the entire argument is the finding by the Eli Lilly
group (5) that pyrrole-3-ethylamine 24 is inert in vivo as a dopaminergic agonist. Without experimental evidence, this inactivity was
rationalized on the basis that this primary amino compound (like
exogenous dopamine) is rapidly destroyed in vivo by monoamine
oxidases. The Lilly group did not report preparation or test data for a
tertiary amine homolog of this pyrrole-3-ethylamine, which would be
refractory to monoamine oxidases and which should, on the basis of
their hypothesis, be an active dopaminergic agent.
In contrast to the Nichols-Lilly ideas, our group at the University
of Iowa argued that the pharmacophore of ergoline systems is the
~-phenethylamine moiety, illustrated (structure 25) with lergotrile.

CH,-CN

Compound 21 is dopaminergically active, but this structure is a poor
choice for the purpose of the study, in that it still contains both the
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(with the diagram showing the eye viewing the appropriate aspect of
the molecule) present the basic amino nitrogen and the indole or
pyrrole ring nitrogen in the same spatial disposition as the amino
nitrogen and the "meta"-OH in the a-conformaiton of dopamine,
illustrated with Newman projections 30 and 31.
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Inspection of molecular models reveals that lergotrile is a rigid system
and overall, the ring system is planar. Referring to structure 26, if a
sight be taken down the ethylamine side chain of the 13-phenethylamine moiety within the molecule, with the nitrogen atom (N-6)
nearest to the eye, the molecule appears as in the Newman projection
27. The entire indole system of the molecule (heavy lines, structure
27) is planar and, as drawn, the benzene ring and the pyrrole ring
project out toward the viewer. The indole ring system is anti to the
amino nitrogen and, according to our analysis of models, the plane of
the benzene-pyrrole rings is approximately 20° out of coplanarity with
the ethylamine side chain. This is an excellent overall approximation
of what we believe to be one of the biologically significant conformers
of the flexible dopamine molecule when it interacts with certain of its
receptors: the so-called a-conformation, shown in structure 28 and
the Newman projection 29. This is very close to the conformation of
the dopamine moiety within the apomorphine molecule.
OH
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In addition, the internitrogen distance in 30 and 31 is approximately
6.2 A, virtually identical with the N-to-meta OH distance of 6.4 A in
dopamine. It can be speculated that dopamine receptors cannot
discriminate between a properly situated indole (or pyrrole) N-H and
a phenolic OH, which is a classic example of bioisosterism.
Discussion is pointless, however, unless these ideas can be used to
design new, potent/active molecules. Our premise, based upon our
conformational ideas, was that the dopaminergic pharmacophore in
ergolines is the heavily shaded portion in structure 32, an indole-4ethylamine moiety 33.
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A significant fact is that the ring nitrogen of indole or pyrrole is not
basic, but is weakly acidic. Thus, chemically, the N-H in 27 is not
unlike a phenolic OH, and we have proposed that in these systems,
this indole ring N-H is bioisosteric with phenol. It occupies the same
position in space as does the "meta"-OH of dopamine in the biologically significant a-conformer shown in structure 29. Moreover, our
past work, as well as that of others, has consistently indicated that the
"meta"-OH of dopamine is unusually important in the interaction of
the molecule with its receptors. Interatomic distance measurements
indicate that the amino-to-meta OH distance in the dopamine
a-conformer is 6.4 A, and in the lergotrile molecule, the distance
between the amino N-6 and the indole ring N-H is almost exactly the
same. Thus, the presence of a biologically potent conformer of the
dopamine molecule can be visualized within the ergoline structure.
Reasonable conformations of the ergoline ring fragments 21 and 22

https://scholarworks.uni.edu/pias/vol93/iss4/3
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Conformational analysis of this indole-4-ethylamine molecule
shows that the flexible molecule can assume (inter alia) a conformation
very similar to that of the analogous sequence of atoms in ergoline
systems such as lergotrile, with the indole ring system coplanar with
the ethylamine side chain, and projecting out toward the viewer, and
with the basic nitrogen and the indole ring system anti, as illustrated
in 34. This simple molecule is very similar to dopamine itself: it is
flexible like dopamine, and it is capable of existing in a dopamine-like
a-conformation.
We synthesized compound 33, bearing n-propyl groups on the
amino group (6). This is an extremely potent/active dopaminergic
agonist. Moreover, its pharmacologic effects at dopamine receptors
qualitatively and quantitatively parallel those of lergotrile and of
certain other ergolines. However, compound 33 lacks effect at serotonin receptors, and it has only weak actions at adrenergic sites. Thus,
we have simplified the pharmacology of the ergot-derived
dopaminergics, and have created a more specific agent with decidedly
fewer side effects.
We noted that, like lergotrile, compound 33 exhibits a 25-30
minute lag period between intravenous administration and production of maximal pharmacologic effect (7). Also, the compound, while
very potent in vivo, showed only extremely weak effects in vitro. In the
case of lergotrile 3, the lag time observed for onset of effect was
concluded to be due to metabolic conversion to a 13-hydroxy
metabolite 6. We speculated that we might be observing similar
metabolic activation of our indole system, and we designed a molecule
35 bearing an OH on the ring position analogous to the 13-position of
lergotrile (8).
H
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HO~N
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Compound 35 had a very potent/active dopaminergic agonist profile,
and the lag time between intravenous administration and maximal
pharmacologic response was brief. The compound, unlike the nonoxygenated system 33, was as active in vitro as it was in vivo (7).
Almost coincident with the communication of our findings on
these compounds, Boissier and Nedelec at Roussel-Uclaf (France) (9)
described high dopaminergic potency for a similar system 36. Here,
the ethylamine side chain of our compound is a part of a piperidine
ring system. This Roussel compound also appeared to be metabolically activated in vivo. The Roussel workers concluded that the indole-4ethylamine moiety of ergolines is the dopaminergic pharmacophore.
Interestingly, the absolute configuration of the chiral center in the
pharmacologically active enantiomer of 36 (as shown) is the same as in
the analogous position of the biologically active, naturally-derived
ergolines (9). However, an equivalent chiral center does not exist in
apomorphine, so that it is not possible to draw structure-activity
conclusions. It is regrettable that our simple indole-4-ethylamines
have no asymmetric center for possible assessment of the Nichols ideas
about stereochemical differences/similarities. Certainly, a weakness of
our work (and, to a lesser extent, of the Roussel work) is the inability
of our designed compounds to answer or to address the apparent
"wrong" stereochemistry between the ergolines and apomorphine.
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And, it must be noted that the Eli Lilly group's argument for the
pyrrole-3-ethylamine moiety's being the pharmacophoric group of the
ergolines was weakened by the almost complete inactivity of the
simple pyrrole-3-ethylamine 24. Both the Lilly-Purdue studies and
the Roussel-Iowa studies represent reasonable, rational approaches to
the problem. Both hypotheses about the nature of the dopaminergic
pharmacophore in ergots seem logical, and both have led to the design
of dopaminergic agonists having potential clinical utility. However,
neither hypothesis was adequate to explain pharmacological results on
all of the compounds studied, and neither hypothesis permitted an
unequivocal, universally acceptable definition of the dopaminergic
pharmacophore. Neither hypothesis by itself nor the pharmacologic
data collected by the proponents of either hypothesis was sufficient to
permit the construction of a graphic representation of the topography
of any dopamine receptor.
The most that we can all agree upon is that significant components
of the ergoline ring system for dopaminergic agonism seem to be the
basic nitrogen (capable of bearing a unit positive charge) and the
indole ring N-H which presumably (like a phenolic OH) can act as a
facile proton donor for hydrogen bonding with a receptor. Moreover, a
molecule incorporating these two groups in an appropriate steric
relationship to each other, with an appropriate inter-nitrogen distance
(approximately 6.4 A) may demonstate dopamine-like effects.
I believe that the results of our twenty years of active study of
dopamine permit us to make some conclusions: Probably many, if not
most, of the dopaminergic agonist structure-pharmacology correlations that have been made in the past (by us and by others) are naive
and do not necessarily reflect the true nature of dopaminergic agonistreceptor interactions, even though we can frequently use these
correlations rationally to design biologically active compounds. It
seems increasingly likely that the dopamine receptor protein molecules possess a high degree of flexibility; the protein chain can exist in
more than one conformation; these conformations are in equilibrium
with each other and are easily interconvertible. The receptors can alter
their molecular shapes and the details of their geometry so as to
compliment and interact with several functional groups in a drug
molecule. And, depending upon the exact nature of the functionalities in the agonist molecule, the receptor can recognize and
interact with varying absolute configurations of chiral centers. Moreover, a multiplicity of these different agonist-receptor complexes is
capable of eliciting a physiological dopaminergic response. Different
chemical series of dopaminergic agonists may be interacting with the
same geographic area on the receptor protein molecule but, depending upon the chemical nature of the specific chemical series of
agonists, a different conformation of the receptor protein may be
involved. Thus, within a given chemical series of agonists, there may be a
well defined structure-activity and stereochemical correlation. But,
these correlations may disappear when a different chemical series of
agonists is addressed, and a new combination of structural parameters
and stereochemical requirements may apply. If this be true, structural
comparisons and correlations between ergoline derivatives, apomorphine derivatives, and other dopaminergic agonist molecular systems
may not only be meaningless, but actually may be misleading.
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As shown in structure 3 7, we view the dopamine molecule as
comprising three pharmacologically significant structural entities: a
system of phenolic OH group(s); a ring system; and substitutent(s) on
the basic nitrogen, in addition to the absolute three-dimensional
geometry of the molecule . . . the stereochemistry of an asymmetric
center. Modification of one or more of these four parameters, independent of the others, can result in retention, reinforcement, or
destruction of dopaminergic agonise activity of the molecule. We
believe that if one parameter (e.g., the phenolic OH groups) is
modified so as to destroy dopaminergic activity, then one or more of
the other parameters (e.g., the nitrogen substituents or the absolute
configuration of an asymmetric center) may be modified at the same
time, such that the dopaminergic agonise effect will be retained in the
molecule. This view derives from the concept that the dopamine
receptors are conformationally highly flexible and can accommodate a
variety of chemical and stereochemical variations of the dopamine
molecule.
If these simple ideas are valid, future structure-activity studies of
dopaminergic agonises will be infinitely more difficult and challenging. However, the rewards are vastly improved therapeutic agents,
not only against the Parkinsonian syndrome, but for treatment of
some types of schizophrenia, essential hypertension, some kinds of
cardiac arrhythmias, and perhaps other challenging ailments, will

https://scholarworks.uni.edu/pias/vol93/iss4/3

make the effort eminently worth doing.
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